Navigation Links
FDA Warns of Fracture Risk With Popular Heartburn Drugs
Date:5/25/2010

Label change to Nexium, Prilosec and other medications should spur patient-doctor discussions, agency says,,

TUESDAY, May 25 (HealthDay News) -- Blockbuster heartburn medications such as Prevacid, Prilosec and Nexium will now carry a warning on their labels linking the drugs to a heightened risk for fractures, the U.S. Food and Drug Administration announced late Tuesday.

The label will advise consumers to use this class of medicines, called proton pump inhibitors (PPIs), carefully, because high doses have been associated with an increased risk of fractures of the hip, wrist and spine, the agency said.

PPIs, which include prescription and over-the-counter drugs, work by blocking stomach acid from being produced. However, as with any drug, this benefit comes with some risk, the FDA said.

"Epidemiology studies suggest a possible increased risk of bone fractures with the use of proton pump inhibitors for one year or longer, or at high doses," Dr. Joyce Korvick, deputy director for safety in FDA's Division of Gastroenterology Products, said in an agency statement.

"Because these products are used by a great number of people, it's important for the public to be aware of this possible increased risk and, when prescribing proton pump inhibitors, health care professionals should consider whether a lower dose or shorter duration of therapy would adequately treat the patient's condition," she said.

Based on a review of the scientific evidence, the agency is instructing the makers of the drugs to change the labels for both the prescription and the over-the-counter versions of the proton pump inhibitors. The FDA based its decision on the results of seven studies, six of which noted a link between PPIs and fracture, primarily among users aged 50 and over.

Proton pump inhibitors include the drugs Nexium (esomeprazole), dexlansoprazole (Dexilant), Prilosec/Zegerid (omeprazole), Prevacid (lansoprazole), Protonix (pantoprazole), and Aciphex (rabeprazole). These medicines are used to treat gastroesophageal reflux disease (GERD), stomach and small intestine ulcers, and inflammation of the esophagus. Over-the-counter versions of Prevacid, Prilosec and Zegerid also fall into this class of drugs.

The FDA is advising consumers to not stop taking PPIs until you have consulted with your doctor. However, patients should be aware of the increased risk for fractures. The highest risk was seen in people taking higher doses of PPIs, or among those who took them for a year or more, the agency said.

For people taking over-the-counter proton pump inhibitors, the FDA said they should only be taken for 14 days to help ease frequent heartburn. If heartburn continues, people should see their doctor. Under no circumstances should over-the-counter PPIs be taken for more than three 14-day periods in a year, the agency said.

Dr. Amar R. Deshpande, an assistant professor of gastroenterology at the University of Miami Miller School of Medicine, said the data behind the FDA decision "is not new."

PPIs may disrupt the body's ability to absorb calcium, which, in turn, can increase the risk for fractures, Deshpande explained. He also believes that this class of drugs is overused and often taken by patients for too long.

There's a need to "be judicious in general, irrespective of this data," Deshpande said. "With PPIs we should really have a targeted endpoint to come off these medications. There is more reason to do that now that we are seeing data that they can have potential side effects."

It is probably also a good idea to shy away from high doses of the heartburn medications, unless absolutely necessary, he said.

"Everything in medicine is a risk/benefit ratio," Deshpande said. "Patients need to talk to their doctor about what they are on the PPI for and look at the risk/benefit ratio and see if they should be on it indefinably or should be able to come off the PPI."

More information

For more on GERD, visit the U.S. National Digestive Diseases Information Clearinghouse.



SOURCES: Amar R. Deshpande, M.D., assistant professor, gastroenterology, University of Miami Miller School of Medicine; May 25, 2010, U.S. Food and Drug Administration, news release


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Warns Cosmetic Doctor about Promoting Anti-Wrinkle Drug before FDA Approval; Unbiased Information on Skin Care a Precious Resource Says SkinTour.com
2. Trupanion Warns: Grapes and Raisins are Deadly to Cats and Dogs
3. SLU doctor warns against St. Johns wort for anxiety
4. The Injury Lawyers Warns on Car Accident Claims Cover
5. Sokolove Warns Consumers: Know the Facts Before You Take the Drug
6. Beware of Getting Caught in the Crossfire, Warns MediCare International
7. Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers
8. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
9. YazTalk Warns Women of Life Threatening Side Effects
10. FDA CONSUMER HEALTH INFORMATION: FDA Warns Consumers About Unsafe Counterfeit Alli
11. Security Choice Warns Against Dangers of Carbon Monoxide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In ... Arts Fighting Challenge with theme event of “K Warriors” on June 4, 2016 at ... , The event is sponsored and hosted by Shaolin Institute and sanctioned by ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Two director-level employees ... YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen ... For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... casual readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven ... tech within the industry, from leading advocates, associations and industry leaders such as ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... students studying complementary medicine. Allison Outerbridge is this year’s Life University ... May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, ... respirators, according to court documents and SEC filings. A jury has returned ... v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: